Clinical Trials Logo

Metastatic Tumors clinical trials

View clinical trials related to Metastatic Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03721341 Active, not recruiting - Metastatic Tumors Clinical Trials

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

SABR-COMET 10
Start date: February 22, 2019
Phase: Phase 3
Study type: Interventional

In patients with a limited oligometastatic burden (cancer has spread but is not yet considered metastatic), emerging evidence suggests that treatment of all sites of disease with ablative therapies can improve patient outcomes, including overall- and progression-free survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10 metastatic deposits appears promising, yet it is unclear if all patients with greater than 3 oligometastatic lesions benefit from ablative therapies in terms of improved Overall Survival (OS), Progression Free Survival (PFS), or quality of life. The purpose of this study is to assess the impact of SABR, compared to standard of care treatment, on overall survival, oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10 metastatic lesions.

NCT ID: NCT02933242 Active, not recruiting - Metastatic Tumors Clinical Trials

Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

Start date: November 2016
Phase: N/A
Study type: Interventional

This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).

NCT ID: NCT01446744 Active, not recruiting - Metastatic Tumors Clinical Trials

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

SABR-COMET
Start date: November 2011
Phase: Phase 2
Study type: Interventional

Stereotactic Ablative Radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. This new technique can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with older treatments. This improvement could help by reducing side effects and by improving the chance of controlling the cancer by more precisely treating the cancer. The purpose of this study is to compare SABR with current approaches of chemotherapy and conventional radiotherapy to assess the impact on overall survival and quality of life.